One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Telemedicine: is the new normal fit for purpose?
doi : 10.1016/S2665-9913(21)00399-4
Volume 4, Issue 1, January 2022, Page e1
Who, what, and when—effective therapy for severe COVID-19
Daniel AKelmensonaRandy QCronb
What does endemic COVID-19 mean for the future of rituximab?
David F LLiewabPhilip CRobinsoncd
Immunity after COVID-19 vaccinations in immunocompromised patients with psoriasis
LauraBoekela
Uricaemia as a surrogate endpoint in gout trials and the treat-to-target approach for gout management
ThomasBardinabPascalRichettecd
Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry
RaphaèleSeroraMarineCamusaJean-HuguesSalmonbChristianRouxcEmmanuelleDernisdAndréBascheVincentGermainfCharlesLeskegSteeveBrousseauhMarie-EliseTruchetethAndréRamoniJacques-EricGottenbergjRenaudFeltenjFabienneCourykAntoineColombeylClémentPratimXavierMarietteaJérÔmeAvouacn
Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses
KristinSchmiedebergadNicolasVuilleumiereSabrinaPaganoeWerner CAlbrichbBurkhardLudewigcfJohannes vonKempisaAndreaRubbert-Rotha
Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab
RenaudFeltenabcFlorianeGallaisdCédricSchleisscEmmanuelChatelusabRose-MarieJavierabLucPijnenburgabChristelleSordetabJeanSibiliaabLaurentArnaudabSamiraFafi-KremerdJacques-EricGottenbergabc
Socioeconomic vulnerability and rheumatoid arthritis in the Philippines
Janine Patricia GRobredoaMichelle Ann BEalabGeraldine TZamorac
FDA approves avacopan for ANCA-associated vasculitis
JenniferThorley
Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial
The CORIMUNO-19 Collaborative groupâ€
Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative
Kathleen MAndersenMScabBenjamin ABatesMDcEmaan SRashidiMHSabAmy LOlexMSdProfRoslyn BMannonMDeRena CPatelMDfProfJasvinderSinghMDghJingSunMDaProfPaul GAuwaerterMDiDerek KNgPhDaProfJodi BSegalMDabkBrian TGaribaldiMDjHemalkumar BMehtaPhDabProfG CalebAlexanderMDabk
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study
Satveer KMahilPhDab*KatieBechmanPhDd*AntonyRaharjaMBBSaClaraDomingo-VilaBSccDavidBaudryMScbProfMatthew ABrownPhDdProfAndrew PCopePhDdTejusDasandiMScaCarlGrahamMReseHatafKhanMSceThomasLechmereMSceProfMichael HMalimPhDeFreyaMeynellMScaEmilyPollockBSccKamilaSychowskaMSccProfJonathan NBarkerMDabSamNortonPhDfJames BGallowayPhDd…ProfCatherine HSmithMDabâ€
Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials
ProfLisa KStampPhDaProfChristopherFramptonPhDaMelanie BMorillonMDbcdWilliam JTaylorPhDeProfNicolaDalbethMDfProfJasvinder ASinghMDghiProfMichaelDohertyMDjProfWeiyaZhangPhDjHelenRichardsonBAkAliyaSarmanovaPhDlProfRobinChristensenPhDbc
The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease
Faye A HCoolesMRCPaProfJohn DIsaacsFRCPab
